Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage
Authors:
- Saumya Ranjan SatrusalSSSaumya Ranjan Satrusal
- Arpita BanerjeeABArpita Banerjee
- Arpon BiswasABArpon Biswas
- Gaurava SrivastavaGSGaurava Srivastava
- Indranil ChatterjeeICIndranil Chatterjee
- Muqtada Ali KhanMKMuqtada Ali Khan
- Biswajit MandalBMBiswajit Mandal
- Kiran TripathiKTKiran Tripathi
- Abhipsa SinhaASAbhipsa Sinha
- Ayushi VermaAVAyushi Verma
- Priyanka RaiPRPriyanka Rai
- Mahmood AkbarMAMahmood Akbar
- 25 August 2026
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 34 (11) , 6513-6560
Abstract
No abstract availableFunding Information
- Indian Council of Medical Research
This publication has 87 references indexed in Scilit:
- Transwell In Vitro Cell Migration and Invasion Assays2023
- Clinical hematological and biochemical parameters in Swiss, BALB/c, C57BL/6 and B6D2F1 Mus musculusAnimal Models and Experimental Medicine, 2020
- Tazemetostat: First ApprovalDrugs, 2020
- Improved side‐chain torsion potentials for the Amber ff99SB protein force fieldProteins: Structure, Function, and Bioinformatics, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- GROMACS: Fast, flexible, and freeJournal of Computational Chemistry, 2005
- Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy functionJournal of Computational Chemistry, 1998
- LINCS: A linear constraint solver for molecular simulationsJournal of Computational Chemistry, 1997
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996
- Automated docking of flexible ligands: Applications of autodockJournal of Molecular Recognition, 1996